Wolfe Research initiated coverage of AbbVie (ABBV) with an Outperform rating and $205 price target The firm noted that AbbVie sounded ...

Pre-tax profits at AbbVie’s global production facility for Botox, in Westport, last year declined by 27pc to $1.1bn (€1.04bn) ...

2 Dividend Stocks to Buy Hand Over Fist in November was originally published by The Motley Fool Their recent issues are ...

Dividend stocks are attractive for their steady income, stability, and growth potential, especially amid low interest rates ...

On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...

AbbVie (ABBV) shares dip for 7th day, but analysts see buying opportunity after recent setback in schizophrenia drug trials.

Pomp Investments investor Anthony Pompliano discusses the likelihood of a Bitcoin boom on 'The Claman Countdown.' The ...

Aldeyra received an FDA CRL for reproxalap, necessitating an additional study for DED approval. Read why I continue to rate ...

JPMorgan lowered the firm’s price target on AbbVie (ABBV) to $200 from $210 and keeps an Overweight rating on the shares. While the ...

In third was AbbVie’s Skyrizi, with an impressions SOV of 4.52% and 2.4 billion impressions supported by $51.5 million in ...

Possibly the biggest news this week comes from the schizophrenia space, where AbbVie’s emraclidine failed two mid-stage ...

AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...